Keros Therapeutics, Inc. Contract Liability (Deferred Revenue)
Keros Therapeutics, Inc. (KROS) had Contract Liability (Deferred Revenue) of $155.00 thousand as of 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2025-11-05
- 2025-09-30: Contract with Customer, Liability, Current $155.00K.
- 2025-06-30: Contract with Customer, Liability, Current $925.00K.
- 2025-03-31: Contract with Customer, Liability, Current $3.31M.
- 2024-12-31: Contract with Customer, Liability, Current $0.00.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2025-09-30 | $155.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $925.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $3.31M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $0.00 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |